Skip to content Accessibility statement

Epidemiology and Cancer Statistics Group

We are an innovative multi-disciplinary research group at the forefront of applied population-based research.  

Specialising in haematological malignancies (leukaemias, lymphomas and myelomas) we work closely with the NHS to answer key questions of public and scientific concern that cannot be addressed elsewhere. 

Unlike most other cancers, haematological cancers can affect people at any age, from birth through to old age. Our research captures the health experiences of the general population and spans the full spectrum of epidemiology – from disease causes through to their consequences. 

We inform researchers, clinicians, patients and the public about the characteristics and outcomes of patients with cancer and our unique datasets yield relevant national and international evidence.

Our research

Our unique real-time clinical data, supplemented by information about experiences from patients, family members and clinicians, enables essential collaborations. We harness the power of these collaborations to answer the fundamental questions that we have about cancer and how it affects us.

Our news

News

7 October 2025

The NIHR Biomedical Research Centre (BRC) Haematology Theme Meeting, held on 3rd October 2025 at the National STEM Learning Centre, brought together leading laboratory researchers, clinicians, epidemiologists, and data scientists to share progress and discuss emerging results.

News

4 September 2025

People diagnosed with multiple myeloma – one of the most common forms of blood cancer – are now living nearly twice as long on average as they were in 2005, according to a new study. The research, led by the University of York and funded by Cancer Research UK and Blood Cancer UK, found that median survival for people with myeloma rose from 2.4 years in 2005 to 4.5 years in 2019. The findings, published in Haematologica, are based on data from more than 3,700 UK patients in England.

News

12 March 2025

On 3 February 2025, Lancet Haematology published results from the MDS-RIGHT consortium.This is an important study showing that ESA treatment has a significant effect on survival, and that it is important to start ESA before RCBT, if possible, to yield the best effect of ESA. Avoiding RBCT is associated with significantly better Health Related Quality of Life (HRQoL).

People
What's happening
Twitter

Contact us

Helen Cohen

ECSG Research Administrator